Abstract: The present disclosure provides allogeneic cells that cause reduced risks of graft-versus-host disease (GVHD) and reduced risk of CD8 and NK cell rejections, for example, when used to treat diseases, such as cancer and/or autoimmune disease, in a patient. The allogeneic cells may be genetically engineered to reduce the expression or activity of CD58. Methods of preparing and using such allogeneic cells are also provided.

Abstract: A clinch nut is used to attach a first panel and a second panel with a space therebetween for accepting a liquid primer. The body has a nut face for abutting a first panel and a threaded aperture through the nut body for receiving a threaded bolt. The nut face has grooves into which the first panel is deformed to clinch the nut body to the first panel. An abutment rises from the nut face a distance greater than the thickness of the first panel so that upon the bolting of the second panel to the first panel by the insertion of the threaded bolt into the threaded aperture of the nut body, the second panel will be spaced from the first panel by the abutment thereby assuring that the liquid primer can flow between the first and second panels.

Abstract: A clinch nut is used to attach a first panel and a second panel with a space therebetween for accepting a liquid primer. The body has a nut face for abutting a first panel and a threaded aperture through the nut body for receiving a threaded bolt. The nut face has grooves into which the first panel is deformed to clinch the nut body to the first panel. An abutment rises from the nut face a distance greater than the thickness of the first panel so that upon the bolting of the second panel to the first panel by the insertion of the threaded bolt into the threaded aperture of the nut body, the second panel will be spaced from the first panel by the abutment thereby assuring that the liquid primer can flow between the first and second panels.